Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Equity (2016 - 2025)

Ligand Pharmaceuticals' Return on Equity history spans 14 years, with the latest figure at 0.13% for Q4 2025.

  • For Q4 2025, Return on Equity rose 16.0% year-over-year to 0.13%; the TTM value through Dec 2025 reached 0.13%, up 16.0%, while the annual FY2025 figure was 0.13%, 14.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.13% at Ligand Pharmaceuticals, up from 0.05% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.13% in Q4 2025 and bottomed at 0.09% in Q1 2025.
  • The 5-year median for Return on Equity is 0.02% (2023), against an average of 0.01%.
  • The largest annual shift saw Return on Equity fell -6bps in 2022 before it increased 16bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.02% in 2021, then crashed by -69bps to 0.04% in 2022, then surged by 94bps to 0.0% in 2023, then crashed by -1429bps to 0.04% in 2024, then soared by 440bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for LGND's Return on Equity are 0.13% (Q4 2025), 0.05% (Q3 2025), and 0.08% (Q2 2025).